Core Insights - CrowdStrike's shares fell 7% after issuing a weaker-than-expected revenue forecast despite a nearly 20% increase in revenue for the fiscal first quarter [1][2] - The company reported a net loss of $110.2 million, or 44 cents per share, compared to a net income of $42.8 million, or 17 cents per share in the same quarter last year [1] - CrowdStrike raised its full-year earnings guidance while maintaining its revenue expectations, projecting adjusted earnings per share of $3.44 to $3.56 and revenue of $4.74 billion to $4.81 billion [3] Financial Performance - For the fiscal first quarter, revenue was $1.10 billion, matching expectations, while adjusted earnings per share were 73 cents, exceeding the expected 65 cents [5] - The company anticipates adjusted earnings per share of 82 to 84 cents for the current quarter, with revenue projected between $1.14 billion and $1.15 billion, slightly below analyst expectations [2] Strategic Actions - CrowdStrike announced a $1 billion share buyback program, reflecting confidence in its future and commitment to its mission [3][4] - As of the latest close, CrowdStrike's stock has increased by 43% in 2025, significantly outperforming the S&P 500 index, which gained less than 2% [4]

Group 1: Share Buyback Details - Sanoma Corporation executed a share buyback on 03 June 2025, acquiring 200 shares at an average price of EUR 9.4200 per share, totaling a cost of EUR 1,884.00 [1] - The company now holds a total of 789,188 of its own shares, including those acquired on 03 June 2025 [2] Group 2: Company Overview - Sanoma is described as an innovative and agile learning and media company, impacting millions daily and committed to sustainability [2] - The company offers a range of learning products and services, including printed and digital content for various educational levels, aiming for business growth [3] - Sanoma operates across Europe with nearly 5,000 employees and reported net sales of approximately EUR 1.3 billion in 2024, with an operational EBIT margin of 13.4% excluding PPA [4]

Core Viewpoint - Aalberts has initiated a share buyback program, repurchasing shares to enhance shareholder value and intends to cancel the repurchased shares [1][2]. Group 1: Share Buyback Details - Aalberts repurchased 2,500 shares from May 26 to May 30, 2025, for a total of EUR 77,389, averaging EUR 30.96 per share [1]. - The total share buyback program, announced on February 27, 2025, is set for EUR 75 million, starting on February 28, 2025, and concluding by October 24, 2025 [2]. - As of May 30, 2025, a cumulative total of 1,837,869 shares has been repurchased for EUR 54,832,159 [2]. Group 2: Execution and Compliance - An intermediary has been engaged to conduct the share repurchases in the open market, independent of Aalberts [3]. - The buyback program is executed within the authority granted by the Annual General Meeting on May 23, 2024, and adheres to the Market Abuse Regulation and safe harbour parameters [3]. Group 3: Additional Information - Weekly progress of the share buyback can be tracked on the company's dedicated website [4]. - The press release is issued in compliance with EU regulations regarding disclosure and reporting obligations for buyback programs [5].

Core Viewpoint - Genmab's stock saw a nearly 4% increase following positive clinical trial results for its drug Rina-S, aimed at treating advanced uterine cancer, and an update on its share buyback program [1][2][5] Group 1: Clinical Trial Results - Genmab announced phase 1/2 clinical trial results for Rina-S, showing a confirmed objective response rate of 50% in patients with advanced uterine cancer who had prior treatments [2] - Study investigator Ira Winer highlighted the encouraging data from the trial, supporting further development of Rina-S as a potential therapy for advanced and recurrent endometrial cancer [4] Group 2: Share Buyback Program - Genmab updated investors on its share buyback program, which allows for the repurchase of up to 2.2 million shares by July 10, 2023, with nearly 2.08 million shares already bought for over 2.7 billion Danish kronor (approximately $411 million) [5] Group 3: Future Outlook - The combination of positive clinical trial results and the aggressive share buyback indicates that Genmab is confident in its development pipeline and future prospects [6][7]

PRESS RELEASE Paris, 2 June 2025 In accordance with Article 5 of Regulation (EU) No 596/2014 on Market Abuse and Article 3 (3) of Delegated Regulation (EU) 2016/1052 supplementing Regulation (EU) No 596/2014 through regulatory technical standards concerning the conditions applicable to buyback programs and stabilization measures, BNP Paribas informs the market of the following transactions in own shares: Name of issuerIdentification code of issuer (Legal Entity Identifier)Day of transactionIdentification co ...

Group 1 - Sanoma Corporation executed a share buyback on June 2, 2025, acquiring 6,000 shares at an average price of €9.47 per share, totaling a cost of €56,820 [1] - The company now holds a total of 788,988 of its own shares following this acquisition [2] - Sanoma's net sales for 2024 were approximately €1.3 billion, with an operational EBIT margin excluding PPA of 13.4% [4] Group 2 - Sanoma is committed to sustainability, aligning its strategy with the UN Sustainable Development Goals and the UN Global Compact [2] - The company offers a range of learning products and services aimed at enhancing educational outcomes for children [3] - Sanoma operates across Europe with a workforce of nearly 5,000 professionals [4]

Group 1 - JDE Peet's has repurchased 21,765 shares from May 26, 2025, to May 30, 2025, at an average price of EUR 23.41 per share, totaling EUR 0.5 million [1] - The total number of shares repurchased under the buyback program to date is 3,668,535 ordinary shares for a total consideration of EUR 68.6 million [2] - The share buyback program is part of a larger EUR 250 million initiative announced on March 3, 2025 [1][2] Group 2 - JDE Peet's is the world's leading pure-play coffee and tea company, serving approximately 4,400 cups of coffee or tea per second [3] - The company operates in over 100 markets with a portfolio of over 50 brands, including L'OR, Peet's, Jacobs, and Douwe Egberts [3] - In 2024, JDE Peet's generated total sales of EUR 8.8 billion and employed more than 21,000 employees globally [3]

Group 1 - IBA has initiated a share buyback program to repurchase up to 650,000 ordinary shares to fulfill obligations under long-term incentive plans for management and certain personnel [2][3] - The company repurchased a total of 16,651 shares between May 27 and May 28, 2025, at an average price of €12.19 per share, totaling €203,014.21 [3] - The total number of treasury shares held by IBA amounts to 1,015,552, representing 3.35% of total issued shares, which are 30,282,218 [3] Group 2 - IBA is a leader in particle accelerator technology, specializing in proton therapy, industrial sterilization, radiopharmaceuticals, and dosimetry [4] - The company is based in Louvain-la-Neuve, Belgium, and employs approximately 2,100 people globally [4] - IBA is listed on the pan-European stock exchange EURONEXT [5]

Core Viewpoint - Wix.com Ltd experienced a significant stock pullback of 16% following an earnings report that missed expectations on earnings but exceeded revenue forecasts, leading to a weaker-than-expected guidance for the upcoming quarter [1][2]. Group 1: Earnings and Guidance - The stock started trading just above $150 but fell after the earnings report, despite a revenue beat [1]. - Analysts noted that the softer Q2 guidance is likely more about conservatism than actual deterioration in business fundamentals [4]. - First-quarter revenue growth was reported at 13%, surpassing guidance by 60 basis points, with notable growth in the Partners segment at 24% year-over-year [3]. Group 2: Analyst Sentiment and Price Targets - Analysts are maintaining or becoming more bullish on Wix, with firms like RBC Capital Markets and Cantor Fitzgerald reiterating Buy or Outperform ratings [2]. - JMP Securities set a target price of $250, indicating a potential upside of approximately 65% from current levels [3]. - The average 12-month stock price forecast is $226.16, suggesting a 48.63% upside from the current price of $152.16 [7]. Group 3: Business Momentum and Buyback Program - The recent pullback is viewed as an attractive entry point for investors, with the company reaffirming its full-year 2025 guidance for bookings growth between 11% and 13% [5]. - New user cohort bookings increased by 12% year-over-year, attributed to a rise in users and improved product fundamentals [6]. - Wix announced an expansion of its share buyback program, signaling management's belief that the stock is undervalued [8][9]. Group 4: Future Outlook - Despite the recent earnings miss, Wix continues to show strong execution with growing revenue, accelerating bookings, and improving user engagement [11]. - The upcoming summer season and returning investor interest in high-quality tech stocks may provide a favorable environment for Wix to recover and potentially reach analyst-targeted price ranges of $230 to $250 [12].

Core Points - Crédit Agricole S.A. is launching its annual capital increase reserved for employees globally [1] - The capital increase will allow 190,000 eligible employees and retired former employees to subscribe to new shares at a discounted price [2] - The subscription price will be set at the arithmetic mean of opening share prices from May 26 to June 20, 2025, with a 20% discount [2] - The subscription period is from June 24 to July 8, 2025 [2] - New shares will be issued on August 28, 2025, and will be eligible for dividends for the 2025 financial year [3] - A maximum of 32 million shares will be issued, with a par value of €96 million [3] - Following the capital increase, a share buyback operation will be conducted to mitigate dilution, pending ECB approval [3] - This initiative is part of the Group's employee profit-sharing policy related to financial performance [3]